New Multiplex Panel for Accurate Cardiovascular Risk Stratification
Predict Cardiovascular Events with the SomaLogic CVD 2º Risk Panel
SomaLogic is at the forefront of the proteomics revolution. Our SOMAscan® Assay measures thousands of proteins simultaneously. It is a powerful tool for biomarker discovery and elucidating biological mechanisms. SomaLogic Diagnostics extends our biomarker discovery programs by developing multiplex panel assays with disease-specific algorithms that provide actionable information. Our future tests will aid in the diagnosis, monitoring response to treatment, prognosis, and risk stratification to help manage chronic diseases and maintain wellness for the best possible outcomes.
SomaLogic Diagnostics will offer the SomaLogic CVD 2º Risk Panel in our CLIA-certified laboratory in the second half of 2016.
We will alert you when the SomaLogic CVD 2o Risk Panel is available.
Download the SomaLogic CVD 2º Risk Panel Flyer for Drug Developers.
Download the JAMA Data Summary Flyer.